Indian Pharmaceutical Industry - PowerPoint PPT Presentation

Loading...

PPT – Indian Pharmaceutical Industry PowerPoint presentation | free to view - id: 58b653-NmE1M



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Indian Pharmaceutical Industry

Description:

Indian Pharmaceutical Industry Riding a Growth Wave Domestic players in the Indian pharmaceutical sector are going global. - Ranbaxy is the largest pharmaceutical ... – PowerPoint PPT presentation

Number of Views:1421
Avg rating:3.0/5.0
Slides: 35
Provided by: Defa286
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Indian Pharmaceutical Industry


1
Indian Pharmaceutical Industry Riding a Growth
Wave
2
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

3
India - An Introduction
  • Population
  • States/UTs
  • Geographical Area
  • Languages recognised
  • Business language
  • Per Capita Income
  • GDP

Over 1 bn 35 3.3 mn sq kms 22 English US
534 US 650 bn
SourceCSO Statistics
(at factor cost at current prices) 1USD43.54
INR (as on July 4, 2005)
4
India - Fast pace Growth
  • Largest democracy
  • 4th largest economy by PPP index
  • 6th largest energy consumer
  • ForEx reserves skyrocket from US 42 bn (2001)
    to
  • US 133 bn (February, 2005)
  • GDP growth to continue between 6-8
  • 3rd largest economy by 2050 Goldman Sachs
  • Leading in IT BPO
  • Oil Gas and Biotechnology sunrise industries

5
India - Leading the world
  • Hero Honda - largest manufacturer of motorcycles
  • Moser Baer - among the top three media
    manufacturers
  • in the world
  • Pharmaceutical Industry - 4th largest in world
  • Walmart, GAP, Hilfiger sources more than
  • USD 1bn worth apparel from India
  • 100 Fortune 500 have set RD facilities in India
  • including GE, Delphi, Eli Lilly, HP, Heinz
    and Daimler
  • Chrysler

6
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

7
Pharma Market
Size (2002-03) US 7 bn
Size 2010 (estimated) US 25 bn
CAGR (1995-2002) 16.6
Exports 23 CAGR(1995-2002)
Volume wise 8 of global market 4th
largest in the world
Share of formulations 80
8
Exports
India - Net exporter of pharmaceutical products
Exports (2002-2003) US 2.8 bn
CAGR (over last decade ) 26
Rate of growth (2003) 21
Export destinations US, Germany, Russia, UK
and China
9
Increased RD Focus
Shift from business-driven research to
research-driven business
10
Increasing RD Spend
1996 -2002 Annual recurring RD expense growth
rate 32.3 yoy
11
Resurgence of FDI
100 automatic FDI approvals to aid increased
investment in RD infrastructure by MNCs
12
Quality Assurance in Manufacturing
Manufacturing facilities
  • GMP compliant
  • Approved by international bodies - US FDA, UK
    MCA,
  • South African MCC

13
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

14
Domestic Players
Ranbaxy Largest pharma company in
India Laboratories Annual revenues of US1bn
Dr Reddys Indian company with presence in
Laboratory more than 50 countries
Cipla One of the lowest cost manufacturer
of anti-HIV drugs in
the world
Wockhardt Largest Indian pharmaceutical
company in UK
15
MNC Presence in India
GlaxoSmithKline Leads in 6 of the 10 therapeutic
categories
Pfizer Owns the two largest selling brands
in India
Astra Zeneca Involved in cardiovascular, respir
atory, maternal healthcare pain control and
anasthesia
Aventis Indian manufacturing sites identified
as potential global sourcing units by
global parent company
16
MNC Presence in India
Merck Leader in laboratory reagents market
in India
Novartis Collaborations with Dr Reddys and
Torrent
Wyeth Contract-manufacturing tie-up with
Indian major Bharat Biotech
Sanofi-Synthelabo Present in cardiology,
thrombosis neuropsychiatry
Roche Already invested US 20 mn in India
and plans additional US 7.35 mn in 2004-05
17
MNC Activity in India
  • Novartis AG seeking tie-ups with Indian companies
  • Bristol-Myers to enter India again
  • Aventiss Goa unit to be sourcing hub
  • Pfizer India doubles research investment in India
  • AstraZeneca, Glaxo to make India RD hub
  • Chiron to make India its Asian hub
  • Bayer AG to make India sourcing hub
  • Eli Lilly to make India sourcing hub
  • German major Boehringer Ingelheim to enter India
  • India to be Roche's global hub for bulk drugs

18
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

19
Invest in India
Contract Research
  • USD 70 mn market (2001-02)
  • Growing at 20 per annum
  • Outsourcing - fastest growing
  • area for new investment
  • US 1 bn opportunity by 2010

Clinical research
20
Invest in India
  • Largest pool of trained analytical
  • and development chemists
  • Excellent track record of innovation
  • US FDA approved manufacturing facilities
  • 30-50 cost savings

Custom synthesis
21
Invest in India
  • Global Outsourcing opportunity worth US 15 bn by
    2010
  • Global majors to outsource manufacturing from
    India

API sourcing and contract manufacturing
22
Invest in India
Collaborative RD
  • Pre clinical testing
  • Superior and low cost chemical synthesis
  • skills advantages
  • Clinical trials
  • India to be an outsourcing centre for
    conducting
  • low cost clinical trials

GlaxoSmithKline has RD alliance with Ranbaxy
Laboratories
23
Export from India
Exports drive growth for Indian pharmaceutical
majors
24
Export from India
Generics - The key driver for export growth
25
Partner with India
Marketing alliances - A win-win strategy
Increased market penetration
  • Zydus Cadila has strategic agreement with
    Schering AG
  • Nicholas Piramal has 5 year strategic alliance
    with
  • Biogen Idec

26
Partner with India
New Drug Delivery System (NDDS)
  • Process reengineering expertise
  • Low-cost scientific manpower available
  • Low capital requirement for NDDS research
  • Fast clearances from regulatory authorities

27
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

28
Advantage India
  • Excellent chemical synthesis skills
  • Successful scaling up of laboratory processes to
    plant-size
  • Cost-effective and commercially viable
    non-infringing
  • processes
  • Pool of low-cost and highly skilled medical
    professionals
  • Manufacturing facilities of international
    standards
  • Quick absorption of new technology

29
Indian Pharmaceutical Act
  • Reduction in number of drugs under price control
    to 28 as
  • against 74
  • 100 foreign investment automatically permitted
  • Abolishment of industrial licensing for bulk
    drugs,
  • intermediates and formulations
  • Automatic approval for Foreign Technology
    Agreements

30
Regulatory Scenario
  • IPR/Patent regulations
  • Product patent regime implemented w.e.f January
    2005
  • in compliance with TRIPS
  • Price regulations
  • Price controls decline substantively
  • Product and quality regulations

31
Policy Incentives
  • Tax exemptions at par with IT
  • Reduction in peak custom duties from 30 to 25
  • Increase on rate of depreciation on life saving
  • equipment from 25 to 40
  • Tax holiday for RD companies

32
Union Budget 2005-06
  • Key Features
  • 22 increase in allocation under the National
    Rural Health Mission
  • Formation of a SME Growth Fund to provide equity
    support to small medium units in the
    pharmaceutical biotechnology sectors.
  • Import duty on select equipments used in
    pharmaceutical biotech research reduced from
    20 to 5.
  • 150 weighted deduction on RD expenditure

Fillip to RD initiatives
33
Pharmaceuticals
  • India - An Overview
  • Market and Growth Potential
  • Players
  • Opportunities
  • Why India?
  • Contact in India

34
Contact in India
Confederation of Indian Industry (CII) The
Mantosh Sodhi Centre 23, Institutional Area Lodi
Road New Delhi 110003 Tel 0091 11
24629994-97 Fax 0091 11 24626149/24615693 Email
c.banerjee_at_ciionline.org
About PowerShow.com